Engineered Polypeptides for Ehrlichia Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Ehrlichia infection, particularly using full-length proteins, are laborious, expensive, and not always effective, as they may not detect all infected animals and can be difficult to distinguish between vaccination and infection.
Innovation Solution
Development of non-natural engineered polypeptides, such as E177 and E208, which are more effective in diagnosing Ehrlichia infection, economically producible, and capable of detecting a wide variety of genetic variants of Ehrlichia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length proteins are used for diagnosis, then diagnostic coverage may be improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent divides full-length Ehrlichia proteins into multiple shorter peptide fragments (e.g., 15-50 amino acids). These segmented peptides maintain diagnostic utility while being easier and more cost-effective to produce through synthetic methods rather than complex protein expression and purification protocols.
Solution Approach 2:
The patent extracts specific immunoreactive epitopes from full-length Ehrlichia proteins to create standalone diagnostic peptides. By taking out only the essential antigenic regions, the patent eliminates the need to produce entire proteins, reducing manufacturing complexity while preserving diagnostic capability.
2Reliability
If full-length proteins are used for diagnosis, then antigenic representation may be improved, but production cost and labor increase
Solution Approach 1:
The patent segments full-length proteins into multiple short peptides that collectively represent the antigenic landscape. This segmentation allows each peptide to be synthesized independently using cost-effective chemical methods rather than requiring expensive and labor-intensive recombinant protein production.
Solution Approach 2:
The patent employs short synthetic peptides that are inexpensive to produce and can be rapidly synthesized on demand. These disposable-like peptide reagents replace expensive, hard-to-produce full-length proteins, making diagnostic testing more economically viable for routine use.
3Measurement precision
If multiple individual proteins are tested, then diagnostic confidence increases, but testing complexity increases
Solution Approach 1:
The patent combines multiple immunoreactive peptide fragments into a single multiplex diagnostic assay. By merging the detection of multiple peptides into one test platform, the patent maintains high diagnostic confidence through multi-parameter assessment while eliminating the need for separate testing procedures for each protein.
Solution Approach 2:
The patent creates a universal diagnostic platform that can detect multiple Ehrlichia species and strains simultaneously using a panel of peptide markers. This multi-functional assay provides comprehensive diagnostic confidence without requiring separate specialized tests for different pathogens.
4Stability of the object's composition
If conventional diagnostic tests are used, then standardization is maintained, but point-of-care availability decreases
Solution Approach 1:
The patent uses inexpensive synthetic peptides that can be incorporated into disposable diagnostic devices such as lateral flow strips or microplate assays. These simplified formats enable standardized testing to be performed at point-of-care settings without requiring complex laboratory infrastructure.
Solution Approach 2:
The patent segments diagnostic testing into discrete peptide-based assays that can be performed independently and rapidly. This segmentation allows standardization to be maintained through controlled peptide synthesis and assay protocols while enabling quick turnaround times suitable for point-of-care decision-making.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered polypeptides demonstrate superior seropositivity and immunoreactivity compared to natural E. canis proteins, enabling more accurate diagnosis and potentially distinguishing between vaccination and infection.
Implementation Method 1
The engineered polypeptides demonstrate superior seropositivity and immunoreactivity compared to natural E. canis proteins
Data Source
AI summary
Immunoreactive engineered polypeptides are provided. The engineered polypeptides can be used to diagnose or induce an immune response against E. chaffeensis or E. canis.